Mitochondrial DNA depletion syndromes - Many genes, common mechanisms

Neuromuscular Disorders

Volumn 20, Issue 7, 2010, Pages 429-437

  Suomalainen, Anu ^a,b   Isohanni, Pirjo ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Alpers syndrome; Encephalopathy; Hepatoencephalopathy; Leigh syndrome; Mitochondrial DNA; Mitochondrial DNA depletion syndrome

Indexed keywords

DEOXYGUANOSINE KINASE; DNA DIRECTED DNA POLYMERASE GAMMA; HELICASE; MITOCHONDRIAL PROTEIN; PROTEIN MPV17; RIBONUCLEOTIDE REDUCTASE; SUCCINIC ACID; SUCCINYL COENZYME A SYNTHETASE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; TWINKLE; UBIDECARENONE; UNCLASSIFIED DRUG; MITOCHONDRIAL DNA;

ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; LIPID DIET; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MITOCHONDRIAL DNA DEPLETION SYNDROME; MNGIE SYNDROME; MOLECULAR GENETICS; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE DELETION; GENETICS; METABOLISM;

DNA, MITOCHONDRIAL; GENE DELETION; HUMANS; MITOCHONDRIAL DISEASES;

EID: 77954035632     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.03.017     Document Type: Review

References (88)

1. Morten K.J., Ashley N., Wijburg F., et al. Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion. Mitochondrion 2007, 7:386-395.
2. Moraes C.T., Shanske S., Tritschler H.J., et al. MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991, 48:492-501.
3. Sarzi E., Bourdon A., Chretien D., et al. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 2007, 150:531-534. 534.e1-6.
4. Alberio S., Mineri R., Tiranti V., Zeviani M. Depletion of mtDNA: syndromes and genes. Mitochondrion 2007, 7:6-12.
5. Walker U.A., Bauerle J., Laguno M., et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004, 39:311-317.
6. Spinazzola A., Invernizzi F., Carrara F., et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis 2009, 32:143-158.
7. Gotz A., Isohanni P., Pihko H., et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 2008, 131:2841-2850.
8. Hakonen A.H., Isohanni P., Paetau A., Herva R., Suomalainen A., Lonnqvist T. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain 2007, 130:3032-3040.
9. Poulton J., Holt I.J. 163rd ENMC International Workshop: nucleoid and nucleotide biology in syndromes of mitochondrial DNA depletion myopathy 12-14 December 2008, Naarden, The Netherlands. Neuromuscul Disord 2009, 19:439-443.
10. Poulton J., Hirano M., Spinazzola A., et al. Collated mutations in mitochondrial DNA (mtDNA) depletion syndrome (excluding the mitochondrial gamma polymerase, POLG1). Biochim Biophys Acta 2009, 1792:1109-1112.
11. Saada A., Shaag A., Mandel H., Nevo Y., Eriksson S., Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001, 29:342-344.
12. Mancuso M., Salviati L., Sacconi S., et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 2002, 59:1197-1202.
13. Oskoui M., Davidzon G., Pascual J., et al. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol 2006, 63:1122-1126.
14. Vila M.R., Segovia-Silvestre T., Gamez J., et al. Reversion of mtDNA depletion in a patient with TK2 deficiency. Neurology 2003, 60:1203-1205.
15. Galbiati S., Bordoni A., Papadimitriou D., et al. New mutations in TK2 gene associated with mitochondrial DNA depletion. Pediatr Neurol 2006, 34:177-185.
16. Akman H.O., Dorado B., Lopez L.C., et al. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet 2008, 17:2433-2440.
17. Zhou X., Solaroli N., Bjerke M., et al. Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. Hum Mol Genet 2008, 17:2329-2335.
18. Mandel H., Szargel R., Labay V., et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001, 29:337-341.
19. Eriksson S., Wang L. Molecular mechanisms of mitochondrial DNA depletion diseases caused by deficiencies in enzymes in purine and pyrimidine metabolism. Nucleosides Nucleotides Nucleic Acids 2008, 27:800-808.
20. Freisinger P., Futterer N., Lankes E., et al. Hepatocerebral mitochondrial DNA depletion syndrome caused by deoxyguanosine kinase (DGUOK) mutations. Arch Neurol 2006, 63:1129-1134.
21. Dimmock D.P., Zhang Q., Dionisi-Vici C., et al. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mutat 2008, 29:330-331.
22. Dimmock D.P., Dunn J.K., Feigenbaum A., et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transpl 2008, 14:1480-1485.
23. Pontarin G., Fijolek A., Pizzo P., et al. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci USA 2008, 105:17801-17806.
24. Bourdon A., Minai L., Serre V., et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 2007, 39:776-780.
25. Bornstein B., Area E., Flanigan K.M., et al. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. Neuromuscul Disord 2008, 18:453-459.
26. Kollberg G., Darin N., Benan K., et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord 2009, 19:147-150.
27. Acham-Roschitz B., Plecko B., Lindbichler F., et al. A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy. Mol Genet Metab 2009, 98:300-304.
28. Shaibani A., Shchelochkov O.A., Zhang S., et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol 2009, 66:1028-1032.
29. Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., Suomalainen A. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet 2009, 85:290-295.
30. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999, 283:689-692.
31. Lara M.C., Valentino M.L., Torres-Torronteras J., Hirano M., Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep 2007, 27:151-163.
32. Nishigaki Y., Marti R., Copeland W.C., Hirano M. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 2003, 111:1913-1921.
33. Nishino I., Spinazzola A., Papadimitriou A., et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000, 47:792-800.
34. Blondon H., Polivka M., Joly F., Flourie B., Mikol J., Messing B. Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). Gastroenterol Clin Biol 2005, 29:773-778.
35. Giordano C., Sebastiani M., De Giorgio R., et al. Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 2008, 173:1120-1128.
36. Hirano M., Silvestri G., Blake D.M., et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994, 44:721-727.
37. Papadimitriou A., Comi G.P., Hadjigeorgiou G.M., et al. Partial depletion and multiple deletions of muscle mtDNA in familial MNGIE syndrome. Neurology 1998, 51:1086-1092.
38. Ostergaard E., Christensen E., Kristensen E., et al. Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am J Hum Genet 2007, 81:383-387.
39. Johnson J.D., Mehus J.G., Tews K., Milavetz B.I., Lambeth D.O. Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes. J Biol Chem 1998, 273:27580-27586.
40. Lambeth D.O., Tews K.N., Adkins S., Frohlich D., Milavetz B.I. Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues. J Biol Chem 2004, 279:36621-36624.
41. Elpeleg O., Miller C., Hershkovitz E., et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 2005, 76:1081-1086.
42. Carrozzo R., Dionisi-Vici C., Steuerwald U., et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 2007, 130:862-874.
43. Ostergaard E. Disorders caused by deficiency of succinate-CoA ligase. J Inherit Metab Dis 2008 [epub ahead of print].
44. Ostergaard E., Hansen F.J., Sorensen N., et al. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain 2007, 130:853-861.
45. Morava E., Steuerwald U., Carrozzo R., et al. Dystonia and deafness due to SUCLA2 defect; clinical course and biochemical markers in 16 children. Mitochondrion 2009, 9:438-442.
46. Ostergaard E., Schwartz M., Batbayli M., et al. A novel missense mutation in SUCLG1 associated with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria. Eur J Pediatr 2010, 169:201-205.
47. Korhonen J.A., Pham X.H., Pellegrini M., Falkenberg M. Reconstitution of a minimal mtDNA replisome in vitro. EMBO J 2004, 23:2423-2429.
48. Chinnery P.F., Zeviani M. 155th ENMC Workshop: polymerase gamma and disorders of mitochondrial DNA synthesis, 21-23 September 2007, Naarden, The Netherlands. Neuromuscul Disord 2008, 18:259-267.
49. Van Goethem G., Dermaut B., Lofgren A., Martin J.J., Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001, 28:211-212.
50. Van Goethem G., Martin J.J., Dermaut B., et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003, 13:133-142.
51. Hakonen A.H., Heiskanen S., Juvonen V., et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005, 77:430-441.
52. Winterthun S., Ferrari G., He L., et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology 2005, 64:1204-1208.
53. Luoma P., Melberg A., Rinne J.O., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004, 364:875-882.
54. Naviaux R.K., Nguyen K.V. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol 2004, 55:706-712.
55. Luoma P.T., Luo N., Loscher W.N., et al. Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. Hum Mol Genet 2005, 14:1907-1920.
56. Wanrooij S., Goffart S., Pohjoismaki J.L., Yasukawa T., Spelbrink J.N. Expression of catalytic mutants of the mtDNA helicase Twinkle and polymerase POLG causes distinct replication stalling phenotypes. Nucleic Acids Res 2007, 35:3238-3251.
57. Naviaux R.K., Nyhan W.L., Barshop B.A., et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome. Ann Neurol 1999, 45:54-58.
58. de Vries M.C., Rodenburg R.J., Morava E., et al. Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders due to polymerase gamma (POLG1) mutations. Eur J Pediatr 2007, 166:229-234.
59. de Vries MC, Rodenburg RJ, Morava E, et al. Normal biochemical analysis of the oxidative phosphorylation (OXPHOS) system in a child with POLG mutations: a cautionary note. J Inherit Metab Dis 2008 [epub ahead of print].
60. Horvath R., Hudson G., Ferrari G., et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006, 129:1674-1684.
61. Tzoulis C., Engelsen B.A., Telstad W., et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006, 129:1685-1692.
62. Engelsen B.A., Tzoulis C., Karlsen B., et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008, 131:818-828.
63. Hakonen A.H., Davidzon G., Salemi R., et al. Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. Eur J Hum Genet 2007, 15:779-783.
64. Suomalainen A., Majander A., Wallin M., et al. Autosomal dominant progressive external ophthalmoplegia with multiple deletions of mtDNA: clinical, biochemical, and molecular genetic features of the 10q-linked disease. Neurology 1997, 48:1244-1253.
65. Spelbrink J.N., Li F.Y., Tiranti V., et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001, 28:223-231.
66. Nikali K., Suomalainen A., Saharinen J., et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet 2005, 14:2981-2990.
67. Sarzi E., Goffart S., Serre V., et al. Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. Ann Neurol 2007, 62:579-587.
68. Hakonen A.H., Goffart S., Marjavaara S., et al. Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. Hum Mol Genet 2008, 17:3822-3835.
69. Koskinen T., Santavuori P., Sainio K., Lappi M., Kallio A.K., Pihko H. Infantile onset spinocerebellar ataxia with sensory neuropathy: a new inherited disease. J Neurol Sci 1994, 121:50-56.
70. Lonnqvist T., Paetau A., Valanne L., Pihko H. Recessive Twinkle mutations cause severe epileptic encephalopathy. Brain 2009, 132:1553-1562.
71. Spinazzola A., Viscomi C., Fernandez-Vizarra E., et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006, 38:570-575.
72. Holve S., Hu D., Shub M., Tyson R.W., Sokol R.J. Liver disease in Navajo neuropathy. J Pediatr 1999, 135:482-493.
73. Vu T.H., Tanji K., Holve S.A., et al. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome?. Hepatology 2001, 34:116-120.
74. Karadimas C.L., Vu T.H., Holve S.A., et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet 2006, 79:544-548.
75. Spinazzola A., Santer R., Akman O.H., et al. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. Arch Neurol 2008, 65:1108-1113.
76. El-Hattab AW, Li FY, Schmitt E, Zhang S, Craigen WJ, Wong LJ. MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations. Mol Genet Metab 2009 [epub ahead of print].
77. Navarro-Sastre A., Martin-Hernandez E., Campos Y., et al. Lethal hepatopathy and leukodystrophy caused by a novel mutation in MPV17 gene: description of an alternative MPV17 spliced form. Mol Genet Metab 2008, 94:234-239.
78. Wong L.J., Brunetti-Pierri N., Zhang Q., et al. Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy. Hepatology 2007, 46:1218-1227.
79. Dallabona C, Marsano RM, Arzuffi P, et al. Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator. Hum Mol Genet 2010 [epub ahead of print].
80. Parini R., Furlan F., Notarangelo L., et al. Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. J Hepatol 2009, 50:215-221.
81. Kaji S., Murayama K., Nagata I., et al. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol Genet Metab 2009, 97:292-296.
82. Delarue A., Paut O., Guys J.M., et al. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 2000, 4:67-71.
83. Kayihan N., Nennesmo I., Ericzon B.G., Nemeth A. Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant 2000, 4:211-214.
84. Wolf N.I., Rahman S., Schmitt B., et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009, 50:1596-1607.
85. Lara M.C., Weiss B., Illa I., et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006, 67:1461-1463.
86. Hirano M., Marti R., Casali C., et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006, 67:1458-1460.
87. Yavuz H., Ozel A., Christensen M., et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 2007, 64:435-438.
88. Bulst S., Abicht A., Holinski-Feder E., Müller-Ziermann S., Koehler U., Thirion C., et al. In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. Hum Mol Genet 2009, 18:1590-1599.